143 related articles for article (PubMed ID: 29788066)
1. Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study.
Ocampo A; Domingo P; Fernández P; Diz J; Barberá JR; Sepúlveda MA; Salgado X; Rodriguez M; Santos J; Yzusqui M; Mayorga MI; Lorenzo JF; Bahamonde A; Bachiller P; Martínez E; Rozas N; Torres C; Muñoz A; Casado A; Podzamczer D
J Antimicrob Chemother; 2018 Aug; 73(8):2171-2176. PubMed ID: 29788066
[TBL] [Abstract][Full Text] [Related]
2. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
Brunetta J; Moreno Guillén S; Antinori A; Yeni P; Wade B; Johnson M; Shalit P; Ebrahimi R; Johnson B; Walker I; De-Oertel S
Patient; 2015 Jun; 8(3):257-67. PubMed ID: 25808940
[TBL] [Abstract][Full Text] [Related]
3. Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate.
Menezes P; Mollan K; Hoffman E; Xie Z; Wills J; Marcus C; Rublein J; Hudgens M; Eron JJ
AIDS Res Hum Retroviruses; 2018 Jun; 34(6):481-485. PubMed ID: 29607652
[TBL] [Abstract][Full Text] [Related]
4. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
Arrabal-Durán P; Rodríguez-González CG; Chamorro-de-Vega E; Gijón-Vidaurreta P; Herranz-Alonso A; Sanjurjo-Sáez M
Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28722790
[TBL] [Abstract][Full Text] [Related]
5. Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides.
Di Biagio A; Riccardi N; Taramasso L; Capetti A; Cenderello G; Signori A; Vitiello P; Guerra M; de Socio GV; Cassola G; Quirino T; Viscoli C
Int J Antimicrob Agents; 2016 Nov; 48(5):551-554. PubMed ID: 27566908
[TBL] [Abstract][Full Text] [Related]
6. Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
Taramasso L; Di Biagio A; Riccardi N; Briano F; Di Filippo E; Comi L; Mora S; Giacomini M; Gori A; Maggiolo F
PLoS One; 2019; 14(10):e0223181. PubMed ID: 31603906
[TBL] [Abstract][Full Text] [Related]
7. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice.
Gatechompol S; Avihingsanon A; Apornpong T; Han WM; Kerr SJ; Ruxrungtham K
AIDS Res Ther; 2019 Apr; 16(1):7. PubMed ID: 30953533
[TBL] [Abstract][Full Text] [Related]
9. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
[TBL] [Abstract][Full Text] [Related]
11. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
Armenia D; Di Carlo D; Calcagno A; Vendemiati G; Forbici F; Bertoli A; Berno G; Carta S; Continenza F; Fedele V; Bellagamba R; Cicalini S; Ammassari A; Libertone R; Zaccarelli M; Ghisetti V; Andreoni M; Ceccherini-Silberstein F; Bonora S; Di Perri G; Antinori A; Perno CF; Santoro MM
J Antimicrob Chemother; 2017 Mar; 72(3):855-865. PubMed ID: 27999048
[TBL] [Abstract][Full Text] [Related]
12. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
Taramasso L; Tatarelli P; Ricci E; Madeddu G; Menzaghi B; Squillace N; De Socio GV; Martinelli C; Gulminetti R; Maggi P; Orofino G; Vichi F; Di Biagio A; Bonfanti P;
BMC Infect Dis; 2018 Jul; 18(1):357. PubMed ID: 30064371
[TBL] [Abstract][Full Text] [Related]
13. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.
Hagins D; Orkin C; Daar ES; Mills A; Brinson C; DeJesus E; Post FA; Morales-Ramirez J; Thompson M; Osiyemi O; Rashbaum B; Stellbrink HJ; Martorell C; Liu H; Liu YP; Porter D; Collins SE; SenGupta D; Das M
HIV Med; 2018 Nov; 19(10):724-733. PubMed ID: 30101539
[TBL] [Abstract][Full Text] [Related]
14. Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114.
Pérez-Hernández IA; Palacios R; Mayorga M; González-Doménech CM; Castaño M; Rivero A; Del Arco A; Lozano F; Santos J
J Int AIDS Soc; 2014; 17(4 Suppl 3):19795. PubMed ID: 25397539
[TBL] [Abstract][Full Text] [Related]
15. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
Behrens G; Maserati R; Rieger A; Domingo P; Abel F; Wang H; Pearce G
Antivir Ther; 2012; 17(6):1011-20. PubMed ID: 22910324
[TBL] [Abstract][Full Text] [Related]
16. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
[TBL] [Abstract][Full Text] [Related]
17. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.
Palacios R; Pérez-Hernández IA; Martínez MA; Mayorga ML; González-Domenech CM; Omar M; Olalla J; Romero A; Romero JM; Pérez-Camacho I; Hernández-Quero J; Santos J
Eur J Clin Microbiol Infect Dis; 2016 May; 35(5):815-9. PubMed ID: 26879392
[TBL] [Abstract][Full Text] [Related]
19. Real World Patient-reported Outcomes in HIV-infected Adults Switching to EVIPLERA®, Because of a Previous Intolerance to cART. PRO-STR Study.
Podzamczer D; Rozas N; Domingo P; Miralles C; den Eynde EV; Romero A; Deig E; Knobel H; Pasquau J; Antela A; Clotet B; Geijo P; de Castro ER; Casado MA; Muñoz A; Casado A; For The Pro-Str Study Group
Curr HIV Res; 2018; 16(6):425-435. PubMed ID: 30760189
[TBL] [Abstract][Full Text] [Related]
20. Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up.
Charpentier C; Lê MP; Joly V; Visseaux B; Lariven S; Phung B; Yéni P; Yazdanpanah Y; Descamps D; Peytavin G; Landman R
PLoS One; 2015; 10(7):e0134430. PubMed ID: 26226257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
